AOD-9604
Medium EvidenceA modified fragment of human growth hormone studied for fat metabolism without growth-promoting effects.
What It Is
AOD-9604 is a synthetic peptide comprising a modified fragment (amino acids 176–191) of human growth hormone, designed to retain the lipolytic (fat-metabolizing) properties of GH without its growth-promoting, IGF-1-elevating, or diabetogenic effects. It acts primarily through beta-3 adrenergic receptors to stimulate lipolysis and inhibit lipogenesis. The FDA granted AOD-9604 GRAS (Generally Recognized As Safe) status for use as a food ingredient, though this designation does not extend to therapeutic drug claims. In the Phase 2b OPAL trial — the largest clinical study of AOD-9604, enrolling 536 obese adults — 1 mg daily subcutaneous AOD-9604 did not achieve statistically significant body weight reduction versus placebo after 12 weeks. However, DEXA scan subgroup analysis showed consistent reduction in subcutaneous fat mass in approximately 30% of participants, suggesting individual variability in beta-3 receptor density or metabolic response. The extensive clinical safety database from over 900 participants across six controlled trials establishes AOD-9604 as well-tolerated with minimal adverse effects. Development as a pharmaceutical obesity drug was discontinued in 2007 after failure to meet primary endpoints, but it remains studied for cartilage repair and osteoarthritis applications. Preclinical studies in rabbit and canine models have demonstrated chondro-protective effects, with AOD-9604 promoting proteoglycan synthesis in articular cartilage without affecting IGF-1 or insulin levels. AOD-9604 was returned to Category 1 compounding eligibility in the United States under the FDA's February 2026 reclassification. No regulatory authority recognizes it as an approved treatment for obesity or weight loss.
Regulatory Status
Returned to Category 1 compounding eligibility under FDA's February 2026 reclassification. May be compounded by 503A/503B pharmacies under physician prescription.
Effective: February 2026
View FDA SourceWhy Researchers Study It
AOD-9604 is studied because it represents a targeted approach to fat metabolism via GH-fragment pharmacology — retaining lipolytic activity while eliminating the unwanted effects of full-length growth hormone. Its established safety profile across 900+ clinical participants and GRAS status make it a low-risk research compound. Current research interest has shifted toward its chondro-protective properties for osteoarthritis and cartilage repair, which may represent a more viable clinical application than its original obesity indication.
Proposed Mechanisms
- Stimulates lipolysis via beta-3 adrenergic receptor activation in adipose tissue
- Inhibits de novo lipogenesis without affecting IGF-1 or insulin levels
- Promotes proteoglycan synthesis in articular cartilage (chondro-protective effect)
- Retains the C-terminal fat-metabolizing domain of hGH (aa 176–191) with a tyrosine substitution
- Does not cross-react with GH receptors, avoiding growth-promoting or diabetogenic effects
Evidence Snapshot
| Study Type | Model | Outcome | Link |
|---|---|---|---|
| Phase 2b RCT (human) | OPAL trial — 536 obese adults, 12 weeks | No statistically significant weight loss vs placebo; DEXA subgroup showed fat mass reduction in ~30% of responders | Source |
| Safety analysis (human) | Pooled data across 6 controlled trials, 900+ participants | Well-tolerated with minimal adverse effects; no IGF-1 elevation or glucose impairment | Source |
| Animal (rabbit) | Cartilage repair — osteoarthritis model | Promoted proteoglycan synthesis and demonstrated chondro-protective effects | Source |
Commonly Discussed Benefits
Safety & Cautions
- Clinical trials for obesity did not meet primary endpoints
- GRAS status is for food use, not as a therapeutic
- Not FDA-approved as a drug
- Ongoing research in cartilage repair applications
Comparisons
See how AOD-9604 compares to related peptides:
Calculator Tools
Use our research tools to explore dosing and reconstitution data:
Citations
- [1] Heffernan M. et al. — Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. Obes Res. 2001 PubMed
- [2] AOD-9604 Peptide: Expert Analysis Reviews Benefits and Side Effects for 2026 — Yahoo Finance PubMed
- [3] AOD-9604 Peptide Complete Guide to Benefits, Dosage & Research (2026) — PeptideDeck PubMed
Continue Your Research
Track your research notes and set reminders in the companion app.
Related Peptides
CJC-1295
Medium EvidenceA growth hormone releasing hormone analog studied for stimulating growth hormone secretion.
Ipamorelin
Medium EvidenceA selective growth hormone secretagogue studied for targeted GH release with fewer side effects than other GH peptides.
MOTS-c
Low EvidenceA mitochondrial-derived peptide studied for metabolic regulation, exercise mimetic effects, and longevity.